What is Celsentri and what is it used for?

 Celsentri (maraviroc) Tablet 300mg is a medication that is used to treat HIV-1 infection in adults. It belongs to a class of drugs called CCR5 antagonists, which work by blocking the CCR5 receptor on the surface of certain immune cells. This receptor is used by the virus to enter and infect these cells, so by blocking it, Celsentri helps to prevent the virus from spreading and reproducing.

Celsentri Tablet 300mg is typically used in combination with other HIV medications, such as protease inhibitors or nucleoside reverse transcriptase inhibitors (NRTIs). The combination of medications used will depend on the individual patient's condition and treatment history.





Before starting Celsentri, your healthcare provider will perform a blood test to determine whether your HIV strain uses the CCR5 receptor. This is because Celsentri only works against HIV strains that use this receptor to enter cells. If your virus uses a different receptor, Celsentri will not be effective.

The recommended dose of Celsentri is typically 300mg taken twice daily, with or without food. It is important to take the medication exactly as prescribed and not to miss any doses. If you do miss a dose, take it as soon as you remember, but do not take two doses at once to make up for the missed dose.

As with all medications, there are potential side effects associated with Celsentri Tablet 300mg . Common side effects may include diarrhea, nausea, fatigue, and headache. These side effects are generally mild and go away on their own, but if they persist or become severe, you should contact your healthcare provider.

Less common but more serious side effects may include liver problems or allergic reactions. If you experience any signs of liver problems, such as yellowing of the skin or eyes, dark urine, or abdominal pain, you should contact your healthcare provider right away. Signs of an allergic reaction may include rash, itching, swelling, or difficulty breathing, and you should seek emergency medical attention if you experience any of these symptoms.

It is important to talk to your healthcare provider about any other medications you are taking before starting Celsentri, as some medications may interact with it and affect its effectiveness or increase the risk of side effects. This includes over-the-counter medications and supplements.

In conclusion, Celsentri is a medication used to treat HIV-1 infection in adults by blocking the CCR5 receptor on certain immune cells. It is typically used in combination with other HIV medications and is effective only against HIV strains that use this receptor to enter cells. While there are potential side effects associated with Celsentri, it can be an effective treatment option when taken as prescribed and under the guidance of a healthcare provider.


Location: New Delhi, Delhi 110038, India

Comments

Post a Comment

Popular posts from this blog

Treatment for Acute Myeloid Leukemia: IDHIFA (Enasidenib)

Image
  In the world of oncology, breakthroughs in targeted therapies have opened new avenues for the treatment of various types of cancer. One such remarkable advancement is the introduction of IDHIFA (Enasidenib), a medication that has shown great promise in the fight against acute myeloidleukemia (AML) . Understanding IDHIFA and AML:  IDHIFA, known by its generic name Enasidenib, is an oral medication that targets a specific mutation known as isocitrate dehydrogenase 2 (IDH2). Mutations in the IDH2 gene are found in approximately 12-20% of AML patients. These mutations lead to the production of an abnormal form of the IDH2 enzyme, which plays a significant role in the development and progression of AML. Approved Indication: IDHIFA is specifically indicated for the treatment of adult patients with relapsed or refractory AML harboring an IDH2 mutation. It is not intended for use in patients with other types of leukemia or those without the IDH2 mutation. Accessing IDHIFA: Obtaining IDHIFA
Read more

What Patients Should Know about Early Access Programs- AlleviareIndia

Image
  Introduction: In the world of medical research and development, new treatments, drugs, and therapies are constantly being developed to address various health conditions. However, the journey from initial development to final approval by regulatory authorities can be a lengthy process, leaving many patients eagerly awaiting access to potentially life-saving treatments. This is where Early Access Programs (EAPs) come into play. In this article, we will explore what patients should consider when participating in an Early Access Program. Understand the Purpose and Eligibility Criteria: Before considering participation in an Early Access Program, it's important to understand its purpose. EAPs are designed to provide access to investigational treatments for patients who have exhausted all other available options and have a serious or life-threatening condition. Familiarize yourself with the eligibility criteria to determine if you meet the necessary requirements. Discuss with
Read more

Abatacept (Orencia)

Image
Abatacept (Orencia) is often prescribed after failure of an anti-rheumatic agent (DMARD), such as methotrexate. But it can be used as first-line therapy. Ebetasip is used to reduce inflammatory symptoms such as swelling, pain, and stiffness. In the long term, it is expected to prevent joint deformity, therefore helping to maintain range of motion. It is often used in patients with moderate to severe rheumatoid arthritis who have not responded to one or more DMARDs, such as methotrexate, or other biologic drugs. DMARDs are usually tried first. Abatacept may be used alone or in combination with DMARDs, which makes it more potent, but not with other biologic drugs (such as TNF inhibitors). Its use in other diseases is still being studied. Unlike some other biologic drugs, abetacept does not block anti-inflammatory proteins such as TNF-alpha antagonists. Abatacept attaches to the surface of inflammatory cells and blocks communication between these cells. By blocking this communicatio
Read more